Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 134Carcinoma, Renal Cell 51Kidney Neoplasms 42Leukemia, Myeloid, Acute 38Neoplasm Metastasis 37Leukemia 33Lymphoma 30Breast Neoplasms 26Ovarian Neoplasms 24Lymphoma, Non-Hodgkin 22Carcinoma, Non-Small-Cell Lung 22Skin Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Neuroblastoma 18Lymphoma, Follicular 18Pancreatic Neoplasms 16Lymphoma, Mantle-Cell 16Leukemia, Lymphocytic, Chronic, B-Cell 16Stomach Neoplasms 14Neoplasms 14Myelodysplastic Syndromes 14Colorectal Neoplasms 13Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, B-Cell, Marginal Zone 12Hodgkin Disease 12Congenital Abnormalities 12Uterine Cervical Neoplasms 11Lymphoma, Large-Cell, Immunoblastic 11Lung Neoplasms 11

Interventions

Doxorubicin 17Cyclophosphamide 16Ifosfamide 11fludarabine 9Radiotherapy 8tazemetostat 4pembrolizumab 4pazopanib 4Gemcitabine 4pegfilgrastim 3cixutumumab 3Trabectedin 3Radiation 3Imatinib Mesylate 3Filgrastim 3Docetaxel 3Dacarbazine 3sargramostim 2liposomal doxorubicin 2fludarabine phosphate 2brostallicin 2aldesleukin 2X-Rays 2Sunitinib 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leukapheresis 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Synovial × aldesleukin × Clear all
NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT03450122 2023-10-16

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡